Pulsenmore Launches At-Home Fertility Monitoring Service with Clalit Health Services, Securing $4.5M Deal

summarizeSummary

Pulsenmore Ltd. announced a strategic commercial agreement with Clalit Health Services, Israel's largest HMO, to launch its Pulsenmore FC at-home follicular monitoring service, potentially valued at $4.5 million over five years.

check_boxKey Events

• Feasibility Trial Success Confirmed

  Clalit Health Services confirmed that the feasibility trial for Pulsenmore FC met the study protocol criteria, paving the way for commercialization.

• New Commercial Agreement Signed

  Pulsenmore and Clalit entered into an 18-month pilot period, followed by a five-year commercial term for the Pulsenmore FC system, an increase from the previous four-year term.

• Significant Revenue Potential

  The agreement is potentially valued at approximately $4.5 million over five years following the pilot, with a minimum annual purchase commitment of 2,000 Pulsenmore FC units.

• Innovative At-Home Fertility Monitoring

  The service will be deployed via Beilinson NEXT, Rabin Medical Center's virtual hospital platform, enabling patients to perform follicular monitoring scans from home with clinical oversight.

auto_awesomeAnalysis

This filing announces a significant commercial agreement for Pulsenmore's at-home follicular monitoring system (Pulsenmore FC) with Clalit Health Services, Israel's largest HMO. The agreement, potentially valued at $4.5 million over five years, follows the successful completion of a feasibility trial, which was a condition of the initial 2021 agreement. This represents a substantial revenue stream for Pulsenmore relative to its market capitalization and validates its technology for a critical application in fertility care. The partnership expands Pulsenmore's existing relationship with Clalit and establishes an innovative care model through a virtual hospital platform, enhancing patient access and convenience for IVF and fertility preservation.